Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Shimai Pharmaceutical Files Hong Kong IPO Prospectus with Advanced T-Cell Engager Pipeline

Fineline Cube May 19, 2026
Company Deals

Youcare Pharmaceutical Commits $147M to Build Nucleic Acid Drug Manufacturing Base in Hangzhou Biopharma Town

Fineline Cube May 19, 2026
Company Deals

BrightGene Pursues Hong Kong Secondary Listing as Global API and Intermediates Leader

Fineline Cube May 19, 2026
Company Deals

Bayzed Health and Meinian Onehealth Forge Strategic Partnership to Build Integrated Full-Cycle Health Management Ecosystem

Fineline Cube May 19, 2026
Company Deals

Ande Healthcare Files Hong Kong IPO Prospectus as Leading Chinese Medical Consumables Innovator

Fineline Cube May 19, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Bayer’s HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment

Fineline Cube May 19, 2026
Company Drug

Sanegene Bio’s C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval

Fineline Cube May 19, 2026
Company Deals

Zhejiang Anglikang Enters R&D Cooperation Agreement with Affinity Biopharmaceutical

Fineline Cube Feb 6, 2024

China-based Zhejiang Anglikang Pharmaceutical Co., Ltd. (SHE: 002940) has entered into a research and development...

Company Deals

Novo Holdings to Acquire Catalent for $16.5 Billion in Strategic Move to Enhance Biopharmaceutical Capacity

Fineline Cube Feb 6, 2024

Novo Holdings, the principal shareholder of Denmark’s Novo Nordisk (CPH: NOVO-B), has announced a definitive...

Company Drug

MSD’s Keytruda Secures 13th Indication Approval in China for Biliary Carcinoma Treatment

Fineline Cube Feb 6, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading US pharmaceutical company, has announced that...

Company Medical Device

Peijia Medical’s Taurus Atlas Pro Balloon Dilation Catheter Approved by NMPA for Pulmonary Valve Procedures

Fineline Cube Feb 6, 2024

Peijia Medical Ltd (HKG: 9996) has announced that it has received marketing approval from the...

Company

MicroPort CRM Receives NMPA Approval for Next-Generation MRI-Safe Implantable Cardiac Pacing System

Fineline Cube Feb 6, 2024

MicroPort Scientific Corp. (HKG: 0853), a leading Shanghai-based medical device company, has announced that its...

Company Deals

Jiangsu Wuzhong Pharmaceutical Partners with SPH KDL Health to Boost Aesthetics Product AestheFill

Fineline Cube Feb 6, 2024

Jiangsu Wuzhong Pharmaceutical Group Corp., (SHA: 600200), a leading Chinese pharmaceutical company, has announced a...

Company Drug

Konruns Pharmaceutical Commences Phase III Clinical Trial for KC1036 in Esophageal Cancer

Fineline Cube Feb 6, 2024

Konruns Pharmaceutical Co., Ltd (SHA: 603590), a Beijing-based pharmaceutical company, has announced the first patient...

Company Deals

Luye Pharma Grants Myung In Pharm Rights to Rivastigmine Patch for Alzheimer’s Treatment in South Korea

Fineline Cube Feb 6, 2024

Luye Pharma Group (HKG: 2186), a Chinese pharmaceutical company, has announced a licensing agreement with...

Company Deals

Abbisko Therapeutics Secures $70 Million Upfront Payment in Licensing Deal with Merck KGaA

Fineline Cube Feb 6, 2024

Shanghai-based biotechnology firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has declared the successful conclusion of...

Company Drug

Joincare Pharmaceuticals Gets Green Light for Semaglutide Biosimilar Clinical Trial

Fineline Cube Feb 6, 2024

Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical entity, has announced that...

Company

Astellas Pharma Inc. Reports 2.1% YOY Growth in Q1-Q3 Fiscal 2023 Revenues

Fineline Cube Feb 6, 2024

Japanese pharmaceutical corporation Astellas Pharma Inc., (TYO: 4503) has announced its financial results for the...

Company Drug

CSPC Pharmaceutical’s rhTNK-tPA Gets NMPA Approval for Acute Ischemic Stroke Treatment

Fineline Cube Feb 5, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...

Company Drug

Roche’s Faricimab Shows Sustained Vision Benefits in Phase III Study for Retinal Vein Occlusion

Fineline Cube Feb 5, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has released interim Phase III data for its bispecific...

Policy / Regulatory

CDE Reports 35.84% Increase in Drug Filings for 2023 with Focus on Innovation and Rare Diseases

Fineline Cube Feb 5, 2024

The Center for Drug Evaluation (CDE) has released its annual drug review report for 2023,...

Company Drug

J&J’s Gene Therapy for X-linked Retinitis Pigmentosa Receives CDE Nod for Breakthrough Designation

Fineline Cube Feb 5, 2024

The Center for Drug Evaluation (CDE) website has indicated that Johnson & Johnson (J&J, NYSE:...

Company

German Tech Giant Merck Launches Digital Hub in Singapore to Boost Healthcare and Semiconductor Research

Fineline Cube Feb 5, 2024

Merck KGaA (ETR: MRK), a leading German technology company, last week inaugurated a digital hub...

Company Drug

Johnson & Johnson’s Talquetamab and Daiichi Sankyo’s Enhertu Eye Priority Review in China

Fineline Cube Feb 5, 2024

The Center for Drug Evaluation (CDE) website has indicated that Johnson & Johnson (J&J, NYSE:...

Company

Biogen Discontinues Aduhelm Development, Redirects Focus to Other Alzheimer’s Therapies

Fineline Cube Feb 5, 2024

Biogen (NASDAQ: BIIB) has announced its decision to discontinue the development and commercialization of its...

Company

Beckton Dickinson’s Q1 Results Affected by Volume-Based Procurement, Life Sciences Growth

Fineline Cube Feb 5, 2024

US-based medical technology company Beckton Dickinson (BD; NYSE: BDX) has reported its financial results for...

Company Drug

SciClone and Menarini File for Import License of Antibacterial Drug Vaborem in Macau

Fineline Cube Feb 5, 2024

SciClone Pharmaceuticals Inc (HKG: 6600) has announced that its Italy-based strategic partner Menarini has submitted...

Posts pagination

1 … 405 406 407 … 668

Recent updates

  • Bayer’s HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment
  • Shimai Pharmaceutical Files Hong Kong IPO Prospectus with Advanced T-Cell Engager Pipeline
  • Sanegene Bio’s C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval
  • Youcare Pharmaceutical Commits $147M to Build Nucleic Acid Drug Manufacturing Base in Hangzhou Biopharma Town
  • Hengrui’s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Bayer’s HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment

Company Deals

Shimai Pharmaceutical Files Hong Kong IPO Prospectus with Advanced T-Cell Engager Pipeline

Company Drug

Sanegene Bio’s C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval

Company Deals

Youcare Pharmaceutical Commits $147M to Build Nucleic Acid Drug Manufacturing Base in Hangzhou Biopharma Town

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.